Publication | Closed Access

Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

OncologyMedicineDose-intensified DoxorubicinPathologyPharmacotherapyAnti-cancer AgentCancer TreatmentEpssg Rms 2005Radiation OncologyPharmacologyCancer ChemotherapyChemotherapyPhase 3